ABL1 and acute lymphoblastic leukemia: Pediatric oncologists often consider the risk of late effects when selecting among upfront therapy options, but we need more data to do so effectively for patients with CML and Ph + ALL, for whom multiple BCR-ABL TKIs may be considered.